Find Erythromycin Stearate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

80RELATED EXCIPIENT COMPANIES

146EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 643-22-1, Abboticine, Bristamycin, Erypar, Dowmycin e, Wyamycin s
Molecular Formula
C55H103NO15
Molecular Weight
1018.4  g/mol
InChI Key
YAVZHCFFUATPRK-YZPBMOCRSA-N
FDA UNII
LXW024X05M

Erythromycin Stearate
Erythromycin Stearate is the stearate salt form of erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin stearate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin stearate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.
1 2D Structure

Erythromycin Stearate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;octadecanoic acid
2.1.2 InChI
InChI=1S/C37H67NO13.C18H36O2/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-17H2,1H3,(H,19,20)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1
2.1.3 InChI Key
YAVZHCFFUATPRK-YZPBMOCRSA-N
2.1.4 Canonical SMILES
CCCCCCCCCCCCCCCCCC(=O)O.CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O
2.1.5 Isomeric SMILES
CCCCCCCCCCCCCCCCCC(=O)O.CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
2.2 Other Identifiers
2.2.1 UNII
LXW024X05M
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Gallimycin

2.3.2 Depositor-Supplied Synonyms

1. 643-22-1

2. Abboticine

3. Bristamycin

4. Erypar

5. Dowmycin E

6. Wyamycin S

7. Pfizer-e

8. Erythrocin Stearate

9. Gallimycin

10. Sk-erythromycin

11. Erythromycin Octadecanoate (salt)

12. Nsc-756747

13. Nci-c55674

14. Lxw024x05m

15. Eratrex

16. Meberyt

17. Qidmycin

18. Ethril

19. Ethril 250

20. Ethril 500

21. Erythromycin Stearate (salt)

22. Erythromycin, Stearate (salt)

23. Erythromycin Steraric Acid Salt

24. Ccris 1504

25. Oe 7

26. Hsdb 4178

27. Einecs 211-396-1

28. Unii-lxw024x05m

29. Stearic Acid, Compd. With Erythromycin (1:1)

30. Bristamycin (tn)

31. Octadecanoic Acid, Compd. With Erythromycin (1:1)

32. Erythromycini Stearas

33. Erythromycin Stearate [usp:ban:jan]

34. Chembl1200510

35. Chebi:34742

36. Hms501d19

37. Erythromycin Stearate [mi]

38. Erythromycin Stearate/ >550ug/mg

39. Hms3264b08

40. Pharmakon1600-01500281

41. Erythromycin Stearate (jp17/usp)

42. Erythromycin Stearate [jan]

43. Erythromycin Stearate [hsdb]

44. Ccg-39117

45. Erythromycin Stearate [vandf]

46. Mfcd00084690

47. Nsc756747

48. Erythromycin Stearate [mart.]

49. Erythromycin Stearate [usp-rs]

50. Erythromycin Stearate [who-dd]

51. Erythromycin Stearate [who-ip]

52. Nsc 756747

53. Ncgc00180891-01

54. Erythromycin Stearate [orange Book]

55. Sbi-0207065.p001

56. Erythromycin Stearate [usp Impurity]

57. Hy-108875

58. Cs-0031206

59. Erythromycin Stearate [usp Monograph]

60. Erythromycini Stearas [who-ip Latin]

61. D02184

62. Erythromycin Stearate For Impurity S Identification

63. Sr-01000872741

64. Sr-01000872741-1

65. W-104851

66. Q27283244

67. Erythromycin Stearate, Antibiotic For Culture Media Use Only

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 1018.4 g/mol
Molecular Formula C55H103NO15
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count16
Rotatable Bond Count23
Exact Mass1017.73277158 g/mol
Monoisotopic Mass1017.73277158 g/mol
Topological Polar Surface Area231 Ų
Heavy Atom Count71
Formal Charge0
Complexity1380
Isotope Atom Count0
Defined Atom Stereocenter Count18
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameErythrocin stearate
Drug LabelERYTHROCIN STEARATE Filmtab tablets (erythromycin stearate tablets, USP) are an antibacterial product containing the stearate salt of erythromycin in a unique film coating.Erythromycin is produced by a strain of Saccharopolyspora erythraea (formerly...
Active IngredientErythromycin stearate
Dosage FormTablet
RouteOral
Strengtheq 250mg base
Market StatusPrescription
CompanyArbor Pharms

2 of 2  
Drug NameErythrocin stearate
Drug LabelERYTHROCIN STEARATE Filmtab tablets (erythromycin stearate tablets, USP) are an antibacterial product containing the stearate salt of erythromycin in a unique film coating.Erythromycin is produced by a strain of Saccharopolyspora erythraea (formerly...
Active IngredientErythromycin stearate
Dosage FormTablet
RouteOral
Strengtheq 250mg base
Market StatusPrescription
CompanyArbor Pharms

4.2 Therapeutic Uses

ITS ACTIONS & USES ARE IDENTICAL TO THOSE OF ERYTHROMYCIN.

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1124


ERYTHROMYCIN MAY BE USEFUL FOR DISSEMINATED GONOCOCCAL DISEASE IN PREGNANT PT WHO IS ALLERGIC TO PENICILLIN... 13 PT...TREATED WITH 500 MG OF ERYTHROMYCIN... STEARATE, GIVEN ORALLY EVERY 6 HR FOR 5 DAYS, SHOWED RAPID CLINICAL & BACTERIOLOGICAL RESPONSES.

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1225


ANTIBACTERIAL AGENT


MEDICATION (VET): ANTIBACTERIAL AGENT


4.3 Drug Warning

...ERYTHROMYCIN & ITS DERIV SELDOM CAUSE SERIOUS ADVERSE REACTIONS.

American Medical Association, AMA Department of Drugs. AMA Drug Evaluations. 4th ed. Chicago: American Medical Association, 1980., p. 1258


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


Gastrointestinal Agents

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Macrolide Antimicrobial [EPC]; Macrolide [EPC]; Macrolides [CS]; Decreased Sebaceous Gland Activity [PE]
5.3 Absorption, Distribution and Excretion

PEAK CONCN IN PLASMA...0.3-0.5 UG/ML 4 HR AFTER ORAL ADMIN OF 250 MG OF BASE & ARE 0.3-1.9 UG/ML AFTER...500-MG TABLET. VARIOUS ESTERS OF ERYTHROMYCIN HAVE BEEN PREPARED TO...IMPROVE STABILITY & FACILITATE ABSORPTION. ...CONCN OF ERYTHROMYCIN IN PLASMA ARE LITTLE DIFFERENT IF STEARATE IS GIVEN ORALLY.

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223


...DIFFUSES READILY INTO INTRACELLULAR FLUIDS, & ANTIBACTERIAL ACTIVITY... ACHIEVED AT...ALL SITES EXCEPT BRAIN & CSF. ...ONE OF FEW ANTIBIOTICS THAT PENETRATES INTO PROSTATIC FLUID, CONCN ARE APPROX 40% OF...PLASMA. EXTENT OF BINDING...TO PLASMA PROTEINS VARIES...PROBABLY EXCEEDS 70% IN ALL.../FORMS OF DRUG/. /ERYTHROMYCIN/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223


ERYTHROMYCIN BASE IS ADEQUATELY ABSORBED FROM UPPER PART OF SMALL INTESTINE; IT IS INACTIVATED BY GASTRIC JUICE... FOOD IN STOMACH DELAYS ITS ULTIMATE ABSORPTION. /ERYTHROMYCIN/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223


ERYTHROMYCIN TRAVERSES PLACENTAL BARRIER; & CONCN OF DRUG IN FETAL PLASMA ARE ABOUT 5-20% OF THOSE IN MATERNAL CIRCULATION. /ERYTHROMYCIN/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223


For more Absorption, Distribution and Excretion (Complete) data for ERYTHROMYCIN STEARATE (11 total), please visit the HSDB record page.


5.4 Metabolism/Metabolites

IT IS HYDROLYZED IN SMALL INTESTINE & IN TISSUES TO YIELD ERYTHROMYCIN.

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1124


5.5 Mechanism of Action

...INHIBIT PROTEIN SYNTH BY BINDING TO 50 S RIBOSOMAL SUBUNITS OF SENSITIVE MICROORGANISMS. ... ASSOC BETWEEN ERYTHROMYCIN & RIBOSOME IS REVERSIBLE BUT TAKES PLACE ONLY WHEN 50 S SUBUNIT IS FREE FROM TRNA MOLECULES BEARING NASCENT PEPTIDE CHAINS. PRODN...OF HIGHLY POLYMERIZED HOMOPEPTIDES IS SUPPRESSED. /ERYTHROMYCIN/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223


THE NONIONIZED FORM OF THE DRUG IS CONSIDERABLY MORE PERMEABLE TO CELLS, & THIS PROBABLY EXPLAINS INCREASED ANTIMICROBIAL ACTIVITY THAT IS OBSERVED AT ALKALINE PH. /ERYTHROMYCIN/

Gilman, A. G., L. S. Goodman, and A. Gilman. (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 6th ed. New York: Macmillan Publishing Co., Inc. 1980., p. 1223


Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Solubilizers

read-more
read-more

Topical

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Granulation

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Taste Masking

read-more
read-more

Controlled & Modified Release

read-more
read-more

Coating Systems & Additives

read-more
read-more

Parenteral

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Co-Processed Excipients

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 643-22-1 / Erythromycin Stearate API manufacturers, exporters & distributors?

Erythromycin Stearate manufacturers, exporters & distributors 1

28

PharmaCompass offers a list of Erythromycin Stearate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Erythromycin Stearate manufacturer or Erythromycin Stearate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Erythromycin Stearate manufacturer or Erythromycin Stearate supplier.

API | Excipient name

Erythromycin Stearate

Synonyms

643-22-1, Abboticine, Bristamycin, Erypar, Dowmycin e, Wyamycin s

Cas Number

643-22-1

Unique Ingredient Identifier (UNII)

LXW024X05M

About Erythromycin Stearate

Erythromycin Stearate is the stearate salt form of erythromycin, a broad-spectrum, topical macrolide antibiotic with antibacterial activity. Erythromycin stearate diffuses through the bacterial cell membrane and reversibly binds to the 50S subunit of the bacterial ribosome. This prevents bacterial protein synthesis. Erythromycin stearate may be bacteriostatic or bactericidal in action, depending on the concentration of the drug at the site of infection and the susceptibility of the organism involved.

Erythromycin stearate [BAN:JAN] Manufacturers

A Erythromycin stearate [BAN:JAN] manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Erythromycin stearate [BAN:JAN], including repackagers and relabelers. The FDA regulates Erythromycin stearate [BAN:JAN] manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Erythromycin stearate [BAN:JAN] API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Erythromycin stearate [BAN:JAN] manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Erythromycin stearate [BAN:JAN] Suppliers

A Erythromycin stearate [BAN:JAN] supplier is an individual or a company that provides Erythromycin stearate [BAN:JAN] active pharmaceutical ingredient (API) or Erythromycin stearate [BAN:JAN] finished formulations upon request. The Erythromycin stearate [BAN:JAN] suppliers may include Erythromycin stearate [BAN:JAN] API manufacturers, exporters, distributors and traders.

click here to find a list of Erythromycin stearate [BAN:JAN] suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Erythromycin stearate [BAN:JAN] USDMF

A Erythromycin stearate [BAN:JAN] DMF (Drug Master File) is a document detailing the whole manufacturing process of Erythromycin stearate [BAN:JAN] active pharmaceutical ingredient (API) in detail. Different forms of Erythromycin stearate [BAN:JAN] DMFs exist exist since differing nations have different regulations, such as Erythromycin stearate [BAN:JAN] USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Erythromycin stearate [BAN:JAN] DMF submitted to regulatory agencies in the US is known as a USDMF. Erythromycin stearate [BAN:JAN] USDMF includes data on Erythromycin stearate [BAN:JAN]'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Erythromycin stearate [BAN:JAN] USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Erythromycin stearate [BAN:JAN] suppliers with USDMF on PharmaCompass.

Erythromycin stearate [BAN:JAN] JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Erythromycin stearate [BAN:JAN] Drug Master File in Japan (Erythromycin stearate [BAN:JAN] JDMF) empowers Erythromycin stearate [BAN:JAN] API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Erythromycin stearate [BAN:JAN] JDMF during the approval evaluation for pharmaceutical products. At the time of Erythromycin stearate [BAN:JAN] JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Erythromycin stearate [BAN:JAN] suppliers with JDMF on PharmaCompass.

Erythromycin stearate [BAN:JAN] CEP

A Erythromycin stearate [BAN:JAN] CEP of the European Pharmacopoeia monograph is often referred to as a Erythromycin stearate [BAN:JAN] Certificate of Suitability (COS). The purpose of a Erythromycin stearate [BAN:JAN] CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Erythromycin stearate [BAN:JAN] EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Erythromycin stearate [BAN:JAN] to their clients by showing that a Erythromycin stearate [BAN:JAN] CEP has been issued for it. The manufacturer submits a Erythromycin stearate [BAN:JAN] CEP (COS) as part of the market authorization procedure, and it takes on the role of a Erythromycin stearate [BAN:JAN] CEP holder for the record. Additionally, the data presented in the Erythromycin stearate [BAN:JAN] CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Erythromycin stearate [BAN:JAN] DMF.

A Erythromycin stearate [BAN:JAN] CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Erythromycin stearate [BAN:JAN] CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Erythromycin stearate [BAN:JAN] suppliers with CEP (COS) on PharmaCompass.

Erythromycin stearate [BAN:JAN] WC

A Erythromycin stearate [BAN:JAN] written confirmation (Erythromycin stearate [BAN:JAN] WC) is an official document issued by a regulatory agency to a Erythromycin stearate [BAN:JAN] manufacturer, verifying that the manufacturing facility of a Erythromycin stearate [BAN:JAN] active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Erythromycin stearate [BAN:JAN] APIs or Erythromycin stearate [BAN:JAN] finished pharmaceutical products to another nation, regulatory agencies frequently require a Erythromycin stearate [BAN:JAN] WC (written confirmation) as part of the regulatory process.

click here to find a list of Erythromycin stearate [BAN:JAN] suppliers with Written Confirmation (WC) on PharmaCompass.

Erythromycin stearate [BAN:JAN] NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Erythromycin stearate [BAN:JAN] as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Erythromycin stearate [BAN:JAN] API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Erythromycin stearate [BAN:JAN] as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Erythromycin stearate [BAN:JAN] and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Erythromycin stearate [BAN:JAN] NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Erythromycin stearate [BAN:JAN] suppliers with NDC on PharmaCompass.

Erythromycin stearate [BAN:JAN] GMP

Erythromycin stearate [BAN:JAN] Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Erythromycin stearate [BAN:JAN] GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Erythromycin stearate [BAN:JAN] GMP manufacturer or Erythromycin stearate [BAN:JAN] GMP API supplier for your needs.

Erythromycin stearate [BAN:JAN] CoA

A Erythromycin stearate [BAN:JAN] CoA (Certificate of Analysis) is a formal document that attests to Erythromycin stearate [BAN:JAN]'s compliance with Erythromycin stearate [BAN:JAN] specifications and serves as a tool for batch-level quality control.

Erythromycin stearate [BAN:JAN] CoA mostly includes findings from lab analyses of a specific batch. For each Erythromycin stearate [BAN:JAN] CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Erythromycin stearate [BAN:JAN] may be tested according to a variety of international standards, such as European Pharmacopoeia (Erythromycin stearate [BAN:JAN] EP), Erythromycin stearate [BAN:JAN] JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Erythromycin stearate [BAN:JAN] USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty